PROOVSTATION
ProovStation and GCA, a major European actor in the transport and industrial logistics sector, signed today a partnership with the aim of creating commercial synergies and supporting the development of the solutions offered by ProovStation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200303005747/en/
The aim of this agreement is to install 30 stations in all the automotive logistic sites of the Groupe Charles André. The deployment will start in April with the installation of the first 2 stations at Corbas (Lyon) and Fleury Merogis (Paris) sites.
For Serge Agneray, Director General of GCA Automotive Logistics division, this new equipment is part of their desire to find innovative solutions with added value for their customers.
GCA's Automotive Logistic branch, in strong growth, is composed of 32 sites in Europe. GCA offers many services to manufacturers, rental companies and vehicle sellers (new and used): transport (with 3.2 million vehicles per year), storage, preparation, maintenance, remarketing, 3D photo, and soon the automated inspection through the solution of ProovStation.
Thanks to their advanced Artificial Intelligence system, ProovStation gantries will allow GCA to offer a fully automated vehicle inspection in 3 seconds. During the passage of the car under the gantry, scratches of the order of a millimeter can be detected, which increases the precision and reduces the cost linked to the inspection.
“We are glad to count GCA as one of our trusted partners and we are looking forward to start this great collaboration which constitutes an important stage in our development. Furthermore, supporting in its activity a key player in the sector such as GCA, is a great recognition for our solution. It brings us closer to our goal, which is: make ProovStation the international standard for the car inspection” says Cédric BERNARD, CEO of ProovStation.
Delphine André, CEO of GCA adds "We are delighted to establish this partnership with ProovStation, a Start Up that shifts the lines in a profession in profound change, and will allow us to benefit our customers from innovative solutions that are always more efficient"
Last January, the Start Up announced its first commercial agreement with BCA Group, the European leader in used vehicle remarketing, aiming to deploy 40 inspection gantries, across Europe, in 13 countries. With this new contract, ProovStation further confirms the strong legitimacy and value of its vehicle inspection solution for the automotive industry.
ABOUT PROOVSTATION
ProovStation is a Deeptech Start Up specialized in Computer Vision. Its ambition is to industrialize, automate and standardize the global automotive inspection process. It reduces the total cost of car inspection and increase the efficiency of the whole process to improve the client and collaborator experience. ProovStation is an automated drive-through bay which detects and analyses vehicle damages. The system generates a 360-degree photo scan of the vehicle in less than 3 seconds and increases the accuracy of damage recognition while reducing inspection costs and greatly improving trust during the transfer of liability. This approach allows to cover all the angles and to capture all damages with an accuracy of one millimeter. The gantry identifies, quantifies and localizes all damages present on the vehicle through its Artificial Intelligence. It delivers a time stamped, geo-located and secured report via the Block Chain. It also offers extra services from a user-friendly dashboard including repair estimate, inspection comparison log, used car pricing, integration and KPI tracking, insurance report and other fully customized options.
ABOUT GCA
Founded in 1932, and currently leaded by Delphine André, granddaughter of its founder, Groupe Charles André (GCA) has developed and diversified its historical activities as road transporter of dangerous good. GCA is now able to intervene on the entire Supply chain in fields like aeronautics, food, automotive, Construction and minerals, chemistry, defense, energy, environment, rail and urban logistics. In 2019, GCA achieved a turnover of 1.4 Billion euros. In 15 countries, GCA employs over 9,400 people. GCA cultivates the values of autonomy, respect for commitments, humility and teamwork. The company attaches great importance to safety, quality of its human resources and training.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005747/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom